Official site of PAION AG. PAION AG is a specialty pharmaceutical company developing and aiming to commercialize innovative drugs for sedation and anesthesia.
We had the pleasure to host a symposium at the 42nd ISICEM congress which was a great success for our company. The great feedback from the participants motivates us to push forward our activities in R&D and commercialization of our products.
Great news! We are excited that the European Commission has approved remimazolam, and thank all healthcare professionals, patients and partners who have been involved in the development of remimazolam.
https://t.co/7B1P7xZ0xS
PAION is proud to participate at the ISICEM 2023, International Symposium on Intensive Care and Emergency Medicine, in Brussels. We are looking forward to seeing you there.
https://t.co/mAGgtMOamM
Great achievement: PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults.
https://t.co/BbV6KzdF1P
Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing.
"We are pleased that our shareholders have voted with a large majority in favour of the implementation of a capital reduction."
https://t.co/CmboqOqn1J
PAION announces submission of New Drug Application for remimazolam by its licensee Cristália in Brasil. Congratulations to our partner Cristália!
https://t.co/o9inhivTVr
We welcome Cristalia as our new remimazolam partner for Latin America!
PAION grants exclusive license to Cristália for development and commercialization of remimazolam in Latin America
https://t.co/87yMbEus8e
PAION assigns Chinese remimazolam patents and sells related future royalties for EUR 20.5 million to Humanwell Healthcare Group
https://t.co/w1f5kKdS4h
PAION submits extension application of marketing authorization for Remimazolam in the indication general anesthesia to the European Medicines Agency
https://t.co/Eec6HgxGQ1
Happy #WorldAnesthesiaDay2021 to all #TeamAnaesthesia! At PAION, our mission is to support and partner with proceduralists and anaesthetists to evolve the field of procedural sedation and anaesthesia together. #WAD2021
@PaionAG launches XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults in the Netherlands
https://t.co/oVG0n3dIfq